Daniel Griffith Anderson is Director at Sigilon Therapeutics, Inc. (SGTX). They have made 1 open-market trade across 1 company since 2021, most recently 2021-06-02.
CIK 0001834111
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SGTX | 2,022,222 | $45.4M |
Shares reported on the most recent Form 4, priced at the 2021-06-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SGTX | SELL | 2021-06-02 | 2021-06-04 | $10.00 | $2.0M | +2.2% | -9.3% | -46.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.